Comment Comment by refurb "The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac."Not sure why this is all that interesting to HN. It's a very early trial and the outcome is "encouraging".Other than a proof of concept that it might work, there is nothing here. parent refurb 3 years ago
Not sure why this is all that interesting to HN. It's a very early trial and the outcome is "encouraging".
Other than a proof of concept that it might work, there is nothing here.